Global siRNA Drugs Market Growth (Status and Outlook) 2025-2031
According to this study, the global siRNA Drugs market size will reach US$ 16700 million by 2031.
Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA at first non-coding RNA molecules, typically 20–24 (normally 21) base pairs in length, similar to miRNA, and operating within the RNA interference (RNAi) pathway. siRNA plays a crucial role in gene silencing and regulation of gene expression. siRNA-based therapeutics have gained significant attention in recent years due to their potential to target specific genes involved in diseases such as cancer, genetic disorders, viral infections, and neurodegenerative diseases. The scope of siRNA drug products encompasses various aspects, including their design, development, testing, and regulatory approval.
Core manufacturers of siRNA Drugs include Alnylam, Novartis, Novo Nordisk, Genzyme and Arrowhead. USA is the largest consumption region, accounting for approximately 57% of the global market, followed by Europe. In terms of product type, subcutaneous injection are the largest market segment, with a share of more than 77%. In terms of product application, the largest application market is nervous system therapy, with a share of approximately 52%.
In-depth analysis of siRNA drug market driving factors
I. Technological breakthroughs: the leap from laboratory to clinic
Delivery system innovation
Lipid nanoparticle (LNP) technology optimization: Early siRNA drugs were limited to the field of rare diseases due to low delivery efficiency and insufficient targeting. In recent years, through technological breakthroughs such as ionized lipid component improvement and PEG modification, LNP can achieve liver-targeted delivery (such as Alnylam's Onpattro) or cross the blood-brain barrier (such as Denali's RVT-1201), significantly broadening the scope of indications.
Popularization of GalNAc coupling technology: This technology achieves efficient liver-targeted delivery by binding to asialoglycoprotein receptors, reducing the frequency of administration (such as Novartis' Leqvio subcutaneous injection once every six months), and promoting siRNA to penetrate into chronic diseases such as cardiovascular and metabolic diseases.
Mature chemical modification technology
Improved stability: Through 2'-O-methyl modification, thiophosphate backbone and other technologies, the half-life of siRNA is extended to several weeks, reducing the risk of immunogenicity.
Reduced off-target effects: AI-assisted sequence design (such as Sirnaomics' AI algorithm) combined with bioinformatics screening improves siRNA specificity and significantly improves clinical safety.
2. Market demand: The outbreak of unmet clinical needs
Indications expand from rare diseases to common diseases
Breakthrough in chronic diseases: Among the approximately 1 billion cardiovascular disease patients worldwide, the market potential for hypercholesterolemia is huge.
New paradigm for tumor treatment: siRNA combined with PD-1 inhibitors (such as Arrowhead's ARO-HIF2) shows synergistic effects in the treatment of renal cancer, pushing tumor immunotherapy into the era of gene regulation.
The rise of personalized medicine: siRNA therapy based on genotyping (such as Alzheimer's disease drugs for patients with APOE4 mutations) meets the needs of precision treatment and increases patients' willingness to pay.
3. Policy support: Improvement of the global regulatory framework
China's policy dividends
'The 14th Five-Year Plan for the Development of the Pharmaceutical Industry': Clearly support the development of new delivery systems and nucleic acid drugs, and provide tax incentives and research and development subsidies.
Priority review channel: CDE implements fast approval for innovative siRNA drugs, such as Sirnaomics' STP705 (treatment of squamous cell skin cancer) included in the breakthrough therapy.
International regulatory coordination
FDA accelerated approval: Onpattro (2018) was approved as the first siRNA drug, turning on the regulatory green light.
EMA adaptive path: Allows conditional approval based on alternative endpoints (such as biomarker changes) to shorten the R&D cycle.
IV. Capital influx: catalytic effect of industrial ecology
Increased investment and financing activity
Global capital layout: 33 financings in the field of small nucleic acid drugs in 2022, with an amount of nearly US$6 billion (such as Sirnaomics IPO raising US$150 million).
MNC giants enter the market: Roche acquires Dicerna for US$2.8 billion, and Novartis and Alnylam reach a US$3.5 billion cooperation to accelerate pipeline development.
CDMO service ecosystem matures
RiboBio, WuXi AppTec: Provide 'one-stop' services from sequence design to cGMP production, reducing R&D costs by more than 50%.
Breakthrough in large-scale production: Through continuous flow synthesis technology, the annual production capacity of siRNA has been increased from grams to kilograms, and the cost per dose has been reduced to less than $100.
V. Competitive landscape: From technical barriers to ecological barriers
Strengthening of patent layout
Core patents for delivery systems: Alnylam owns key technology patent clusters such as LNP and GalNAc, forming a technological monopoly.
Chemical modification patent network: Ionis' 2'-MOE modification and Sirnaomics' GalNAc-siRNA coupling technology build a patent moat.
Cross-border cooperation is accelerating
Pharmaceutical company-biotechnology company alliance: For example, AstraZeneca and Silence Therapeutics cooperate to develop cardiovascular siRNA drugs, sharing R&D risks and benefits.
Collaborative innovation between industry, academia and research: Harvard University and Moderna cooperate to develop RNA editing technology to promote the transformation of basic research to clinical practice.
VI. Challenges and coping strategies
Breakthrough in technical bottlenecks
Improved tissue penetration: Through cell penetrating peptide (CPP) modification or exosome delivery, the problem of siRNA delivery in organs such as the lungs and brain is solved.
Long-term safety assessment: Establish real-time quantitative PCR to monitor off-target effects, and optimize sequence design in combination with single-cell sequencing technology.
Balance between cost and accessibility
Tiered pricing strategy: Adopt the 'patent pool' model (such as MPP) in low-income countries to improve drug accessibility.
In the future, siRNA drugs are expected to become the third largest drug type after small molecules and antibodies, reshaping the biopharmaceutical industry landscape. Companies need to focus on core technology breakthroughs, differentiated indication layout and global cooperation to seize market opportunities.
LPI (LP Information)' newest research report, the “siRNA Drugs Industry Forecast” looks at past sales and reviews total world siRNA Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected siRNA Drugs sales for 2025 through 2031. With siRNA Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world siRNA Drugs industry.
This Insight Report provides a comprehensive analysis of the global siRNA Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on siRNA Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global siRNA Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for siRNA Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global siRNA Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of siRNA Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA at first non-coding RNA molecules, typically 20–24 (normally 21) base pairs in length, similar to miRNA, and operating within the RNA interference (RNAi) pathway. siRNA plays a crucial role in gene silencing and regulation of gene expression. siRNA-based therapeutics have gained significant attention in recent years due to their potential to target specific genes involved in diseases such as cancer, genetic disorders, viral infections, and neurodegenerative diseases. The scope of siRNA drug products encompasses various aspects, including their design, development, testing, and regulatory approval.
Core manufacturers of siRNA Drugs include Alnylam, Novartis, Novo Nordisk, Genzyme and Arrowhead. USA is the largest consumption region, accounting for approximately 57% of the global market, followed by Europe. In terms of product type, subcutaneous injection are the largest market segment, with a share of more than 77%. In terms of product application, the largest application market is nervous system therapy, with a share of approximately 52%.
In-depth analysis of siRNA drug market driving factors
I. Technological breakthroughs: the leap from laboratory to clinic
Delivery system innovation
Lipid nanoparticle (LNP) technology optimization: Early siRNA drugs were limited to the field of rare diseases due to low delivery efficiency and insufficient targeting. In recent years, through technological breakthroughs such as ionized lipid component improvement and PEG modification, LNP can achieve liver-targeted delivery (such as Alnylam's Onpattro) or cross the blood-brain barrier (such as Denali's RVT-1201), significantly broadening the scope of indications.
Popularization of GalNAc coupling technology: This technology achieves efficient liver-targeted delivery by binding to asialoglycoprotein receptors, reducing the frequency of administration (such as Novartis' Leqvio subcutaneous injection once every six months), and promoting siRNA to penetrate into chronic diseases such as cardiovascular and metabolic diseases.
Mature chemical modification technology
Improved stability: Through 2'-O-methyl modification, thiophosphate backbone and other technologies, the half-life of siRNA is extended to several weeks, reducing the risk of immunogenicity.
Reduced off-target effects: AI-assisted sequence design (such as Sirnaomics' AI algorithm) combined with bioinformatics screening improves siRNA specificity and significantly improves clinical safety.
2. Market demand: The outbreak of unmet clinical needs
Indications expand from rare diseases to common diseases
Breakthrough in chronic diseases: Among the approximately 1 billion cardiovascular disease patients worldwide, the market potential for hypercholesterolemia is huge.
New paradigm for tumor treatment: siRNA combined with PD-1 inhibitors (such as Arrowhead's ARO-HIF2) shows synergistic effects in the treatment of renal cancer, pushing tumor immunotherapy into the era of gene regulation.
The rise of personalized medicine: siRNA therapy based on genotyping (such as Alzheimer's disease drugs for patients with APOE4 mutations) meets the needs of precision treatment and increases patients' willingness to pay.
3. Policy support: Improvement of the global regulatory framework
China's policy dividends
'The 14th Five-Year Plan for the Development of the Pharmaceutical Industry': Clearly support the development of new delivery systems and nucleic acid drugs, and provide tax incentives and research and development subsidies.
Priority review channel: CDE implements fast approval for innovative siRNA drugs, such as Sirnaomics' STP705 (treatment of squamous cell skin cancer) included in the breakthrough therapy.
International regulatory coordination
FDA accelerated approval: Onpattro (2018) was approved as the first siRNA drug, turning on the regulatory green light.
EMA adaptive path: Allows conditional approval based on alternative endpoints (such as biomarker changes) to shorten the R&D cycle.
IV. Capital influx: catalytic effect of industrial ecology
Increased investment and financing activity
Global capital layout: 33 financings in the field of small nucleic acid drugs in 2022, with an amount of nearly US$6 billion (such as Sirnaomics IPO raising US$150 million).
MNC giants enter the market: Roche acquires Dicerna for US$2.8 billion, and Novartis and Alnylam reach a US$3.5 billion cooperation to accelerate pipeline development.
CDMO service ecosystem matures
RiboBio, WuXi AppTec: Provide 'one-stop' services from sequence design to cGMP production, reducing R&D costs by more than 50%.
Breakthrough in large-scale production: Through continuous flow synthesis technology, the annual production capacity of siRNA has been increased from grams to kilograms, and the cost per dose has been reduced to less than $100.
V. Competitive landscape: From technical barriers to ecological barriers
Strengthening of patent layout
Core patents for delivery systems: Alnylam owns key technology patent clusters such as LNP and GalNAc, forming a technological monopoly.
Chemical modification patent network: Ionis' 2'-MOE modification and Sirnaomics' GalNAc-siRNA coupling technology build a patent moat.
Cross-border cooperation is accelerating
Pharmaceutical company-biotechnology company alliance: For example, AstraZeneca and Silence Therapeutics cooperate to develop cardiovascular siRNA drugs, sharing R&D risks and benefits.
Collaborative innovation between industry, academia and research: Harvard University and Moderna cooperate to develop RNA editing technology to promote the transformation of basic research to clinical practice.
VI. Challenges and coping strategies
Breakthrough in technical bottlenecks
Improved tissue penetration: Through cell penetrating peptide (CPP) modification or exosome delivery, the problem of siRNA delivery in organs such as the lungs and brain is solved.
Long-term safety assessment: Establish real-time quantitative PCR to monitor off-target effects, and optimize sequence design in combination with single-cell sequencing technology.
Balance between cost and accessibility
Tiered pricing strategy: Adopt the 'patent pool' model (such as MPP) in low-income countries to improve drug accessibility.
In the future, siRNA drugs are expected to become the third largest drug type after small molecules and antibodies, reshaping the biopharmaceutical industry landscape. Companies need to focus on core technology breakthroughs, differentiated indication layout and global cooperation to seize market opportunities.
LPI (LP Information)' newest research report, the “siRNA Drugs Industry Forecast” looks at past sales and reviews total world siRNA Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected siRNA Drugs sales for 2025 through 2031. With siRNA Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world siRNA Drugs industry.
This Insight Report provides a comprehensive analysis of the global siRNA Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on siRNA Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global siRNA Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for siRNA Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global siRNA Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of siRNA Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Intravenous Injection
- Subcutaneous Injection
- Nervous System Therapy
- Endocrine and Metabolic Therapy
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Alnylam
- Novartis
- Novo Nordisk
- Genzyme
- Arrowhead
- Silence
- Sylentis
- Avidity Biosciences
- Sirnaomics
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global siRNA Drugs Market Size 2025-2031
2.1.2 siRNA Drugs Market Size CAGR by Region
2.2 siRNA Drugs Segment by Type
2.2.1 Intravenous Injection
2.2.2 Subcutaneous Injection
2.3 siRNA Drugs Market Size by Type
2.3.1 Global siRNA Drugs Market Size Market Share by Type (2025-2031)
2.3.2 Global siRNA Drugs Market Size Growth Rate by Type (2025-2031)
2.4 siRNA Drugs Segment by Application
2.4.1 Nervous System Therapy
2.4.2 Endocrine and Metabolic Therapy
2.4.3 Others
2.5 siRNA Drugs Market Size by Application (2025-2031)
2.5.1 Global siRNA Drugs Market Size Market Share by Application (2025-2031)
2.5.2 Global siRNA Drugs Market Size Growth Rate by Application (2025-2031)
3 SIRNA DRUGS KEY PLAYERS
3.1 Date of Key Players Enter into siRNA Drugs
3.2 Key Players siRNA Drugs Product Offered
3.3 Key Players siRNA Drugs Funding/Investment Analysis
3.4 Funding/Investment
3.4.1 Funding/Investment by Regions
3.4.2 Funding/Investment by End-Industry
3.5 Key Players siRNA Drugs Valuation & Market Capitalization
3.6 Key Players Mergers & Acquisitions, Expansion Plans
3.7 Market Ranking
3.8 New Product/Technology Launches
3.9 Partnerships, Agreements, and Collaborations
3.10 Mergers and Acquisitions
4 SIRNA DRUGS BY REGIONS
4.1 siRNA Drugs Market Size by Regions (2025-2031)
4.2 United States siRNA Drugs Market Size Growth (2025-2031)
4.3 China siRNA Drugs Market Size Growth (2025-2031)
4.4 Europe siRNA Drugs Market Size Growth (2025-2031)
4.5 Rest of World siRNA Drugs Market Size Growth (2025-2031)
5 UNITED STATES
5.1 United States siRNA Drugs Market Size by Type (2025-2031)
5.2 United States siRNA Drugs Market Size by Application (2025-2031)
6 EUROPE
6.1 Europe siRNA Drugs Market Size by Type (2025-2031)
6.2 Europe siRNA Drugs Market Size by Application (2025-2031)
7 CHINA
7.1 China siRNA Drugs Market Size by Type (2025-2031)
7.2 China siRNA Drugs Market Size by Application (2025-2031)
8 REST OF WORLD
8.1 Rest of World siRNA Drugs Market Size by Type (2025-2031)
8.2 Rest of World siRNA Drugs Market Size by Application (2025-2031)
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 KEY INVESTORS IN SIRNA DRUGS
10.1 Company A
10.1.1 Company A Company Details
10.1.2 Company Description
10.1.3 Companies Invested by Company A
10.1.4 Company A Key Development and Market Layout
10.2 Company B
10.2.1 Company B Company Details
10.2.2 Company Description
10.2.3 Companies Invested by Company B
10.2.4 Company B Key Development and Market Layout
10.3 Company C
10.3.1 Company C Company Details
10.3.2 Company Description
10.3.3 Companies Invested by Company C
10.3.4 Company C Key Development and Market Layout
10.4 Company D
10.5 ……
11 KEY PLAYERS ANALYSIS
11.1 Alnylam
11.1.1 Alnylam Company Details
11.1.2 Alnylam siRNA Drugs Product Offered
11.1.3 Alnylam siRNA Drugs Market Size (2024 VS 2030)
11.1.4 Alnylam Main Business Overview
11.1.5 Alnylam News
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis siRNA Drugs Product Offered
11.2.3 Novartis siRNA Drugs Market Size (2024 VS 2030)
11.2.4 Novartis Main Business Overview
11.2.5 Novartis News
11.3 Novo Nordisk
11.3.1 Novo Nordisk Company Details
11.3.2 Novo Nordisk siRNA Drugs Product Offered
11.3.3 Novo Nordisk siRNA Drugs Market Size (2024 VS 2030)
11.3.4 Novo Nordisk Main Business Overview
11.3.5 Novo Nordisk News
11.4 Genzyme
11.4.1 Genzyme Company Details
11.4.2 Genzyme siRNA Drugs Product Offered
11.4.3 Genzyme siRNA Drugs Market Size (2024 VS 2030)
11.4.4 Genzyme Main Business Overview
11.4.5 Genzyme News
11.5 Arrowhead
11.5.1 Arrowhead Company Details
11.5.2 Arrowhead siRNA Drugs Product Offered
11.5.3 Arrowhead siRNA Drugs Market Size (2024 VS 2030)
11.5.4 Arrowhead Main Business Overview
11.5.5 Arrowhead News
11.6 Silence
11.6.1 Silence Company Details
11.6.2 Silence siRNA Drugs Product Offered
11.6.3 Silence siRNA Drugs Market Size (2024 VS 2030)
11.6.4 Silence Main Business Overview
11.6.5 Silence News
11.7 Sylentis
11.7.1 Sylentis Company Details
11.7.2 Sylentis siRNA Drugs Product Offered
11.7.3 Sylentis siRNA Drugs Market Size (2024 VS 2030)
11.7.4 Sylentis Main Business Overview
11.7.5 Sylentis News
11.8 Avidity Biosciences
11.8.1 Avidity Biosciences Company Details
11.8.2 Avidity Biosciences siRNA Drugs Product Offered
11.8.3 Avidity Biosciences siRNA Drugs Market Size (2024 VS 2030)
11.8.4 Avidity Biosciences Main Business Overview
11.8.5 Avidity Biosciences News
11.9 Sirnaomics
11.9.1 Sirnaomics Company Details
11.9.2 Sirnaomics siRNA Drugs Product Offered
11.9.3 Sirnaomics siRNA Drugs Market Size (2024 VS 2030)
11.9.4 Sirnaomics Main Business Overview
11.9.5 Sirnaomics News
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global siRNA Drugs Market Size 2025-2031
2.1.2 siRNA Drugs Market Size CAGR by Region
2.2 siRNA Drugs Segment by Type
2.2.1 Intravenous Injection
2.2.2 Subcutaneous Injection
2.3 siRNA Drugs Market Size by Type
2.3.1 Global siRNA Drugs Market Size Market Share by Type (2025-2031)
2.3.2 Global siRNA Drugs Market Size Growth Rate by Type (2025-2031)
2.4 siRNA Drugs Segment by Application
2.4.1 Nervous System Therapy
2.4.2 Endocrine and Metabolic Therapy
2.4.3 Others
2.5 siRNA Drugs Market Size by Application (2025-2031)
2.5.1 Global siRNA Drugs Market Size Market Share by Application (2025-2031)
2.5.2 Global siRNA Drugs Market Size Growth Rate by Application (2025-2031)
3 SIRNA DRUGS KEY PLAYERS
3.1 Date of Key Players Enter into siRNA Drugs
3.2 Key Players siRNA Drugs Product Offered
3.3 Key Players siRNA Drugs Funding/Investment Analysis
3.4 Funding/Investment
3.4.1 Funding/Investment by Regions
3.4.2 Funding/Investment by End-Industry
3.5 Key Players siRNA Drugs Valuation & Market Capitalization
3.6 Key Players Mergers & Acquisitions, Expansion Plans
3.7 Market Ranking
3.8 New Product/Technology Launches
3.9 Partnerships, Agreements, and Collaborations
3.10 Mergers and Acquisitions
4 SIRNA DRUGS BY REGIONS
4.1 siRNA Drugs Market Size by Regions (2025-2031)
4.2 United States siRNA Drugs Market Size Growth (2025-2031)
4.3 China siRNA Drugs Market Size Growth (2025-2031)
4.4 Europe siRNA Drugs Market Size Growth (2025-2031)
4.5 Rest of World siRNA Drugs Market Size Growth (2025-2031)
5 UNITED STATES
5.1 United States siRNA Drugs Market Size by Type (2025-2031)
5.2 United States siRNA Drugs Market Size by Application (2025-2031)
6 EUROPE
6.1 Europe siRNA Drugs Market Size by Type (2025-2031)
6.2 Europe siRNA Drugs Market Size by Application (2025-2031)
7 CHINA
7.1 China siRNA Drugs Market Size by Type (2025-2031)
7.2 China siRNA Drugs Market Size by Application (2025-2031)
8 REST OF WORLD
8.1 Rest of World siRNA Drugs Market Size by Type (2025-2031)
8.2 Rest of World siRNA Drugs Market Size by Application (2025-2031)
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 KEY INVESTORS IN SIRNA DRUGS
10.1 Company A
10.1.1 Company A Company Details
10.1.2 Company Description
10.1.3 Companies Invested by Company A
10.1.4 Company A Key Development and Market Layout
10.2 Company B
10.2.1 Company B Company Details
10.2.2 Company Description
10.2.3 Companies Invested by Company B
10.2.4 Company B Key Development and Market Layout
10.3 Company C
10.3.1 Company C Company Details
10.3.2 Company Description
10.3.3 Companies Invested by Company C
10.3.4 Company C Key Development and Market Layout
10.4 Company D
10.5 ……
11 KEY PLAYERS ANALYSIS
11.1 Alnylam
11.1.1 Alnylam Company Details
11.1.2 Alnylam siRNA Drugs Product Offered
11.1.3 Alnylam siRNA Drugs Market Size (2024 VS 2030)
11.1.4 Alnylam Main Business Overview
11.1.5 Alnylam News
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis siRNA Drugs Product Offered
11.2.3 Novartis siRNA Drugs Market Size (2024 VS 2030)
11.2.4 Novartis Main Business Overview
11.2.5 Novartis News
11.3 Novo Nordisk
11.3.1 Novo Nordisk Company Details
11.3.2 Novo Nordisk siRNA Drugs Product Offered
11.3.3 Novo Nordisk siRNA Drugs Market Size (2024 VS 2030)
11.3.4 Novo Nordisk Main Business Overview
11.3.5 Novo Nordisk News
11.4 Genzyme
11.4.1 Genzyme Company Details
11.4.2 Genzyme siRNA Drugs Product Offered
11.4.3 Genzyme siRNA Drugs Market Size (2024 VS 2030)
11.4.4 Genzyme Main Business Overview
11.4.5 Genzyme News
11.5 Arrowhead
11.5.1 Arrowhead Company Details
11.5.2 Arrowhead siRNA Drugs Product Offered
11.5.3 Arrowhead siRNA Drugs Market Size (2024 VS 2030)
11.5.4 Arrowhead Main Business Overview
11.5.5 Arrowhead News
11.6 Silence
11.6.1 Silence Company Details
11.6.2 Silence siRNA Drugs Product Offered
11.6.3 Silence siRNA Drugs Market Size (2024 VS 2030)
11.6.4 Silence Main Business Overview
11.6.5 Silence News
11.7 Sylentis
11.7.1 Sylentis Company Details
11.7.2 Sylentis siRNA Drugs Product Offered
11.7.3 Sylentis siRNA Drugs Market Size (2024 VS 2030)
11.7.4 Sylentis Main Business Overview
11.7.5 Sylentis News
11.8 Avidity Biosciences
11.8.1 Avidity Biosciences Company Details
11.8.2 Avidity Biosciences siRNA Drugs Product Offered
11.8.3 Avidity Biosciences siRNA Drugs Market Size (2024 VS 2030)
11.8.4 Avidity Biosciences Main Business Overview
11.8.5 Avidity Biosciences News
11.9 Sirnaomics
11.9.1 Sirnaomics Company Details
11.9.2 Sirnaomics siRNA Drugs Product Offered
11.9.3 Sirnaomics siRNA Drugs Market Size (2024 VS 2030)
11.9.4 Sirnaomics Main Business Overview
11.9.5 Sirnaomics News
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. siRNA Drugs Market Size CAGR by Region (2025-2031) ($ millions)
Table 2. Major Players of Intravenous Injection
Table 3. Major Players of Subcutaneous Injection
Table 4. Global Market Size by Type (2025-2031) ($ millions)
Table 5. Global siRNA Drugs Market Size Market Share by Type (2025-2031)
Table 6. Global siRNA Drugs Market Size by Application (2025-2031) ($ millions)
Table 7. Global siRNA Drugs Market Size Market Share by Application (2025-2031)
Table 8. Date of Global Key Players Enter into siRNA Drugs Market
Table 9. Global Key Players siRNA Drugs Product Offered
Table 10. Key Players siRNA Drugs Funding/Investment (Million USD)
Table 11. Funding/Investment by Regions
Table 12. Funding/Investment by End-Industry
Table 13. Key Players siRNA Drugs Valuation & Market Capitalization (Million USD)
Table 14. Key Players Mergers & Acquisitions, Expansion Plans
Table 15. siRNA Drugs New Product/Technology Launches
Table 16. siRNA Drugs Industry Partnerships, Agreements, and Collaborations
Table 17. siRNA Drugs Industry Mergers and Acquisitions
Table 18. Global siRNA Drugs Market Size by Regions 2025-2031 ($ millions)
Table 19. Global siRNA Drugs Market Size Market Share by Regions 2025-2031
Table 20. United States siRNA Drugs Market Size by Type (2025-2031) ($ millions)
Table 21. United States siRNA Drugs Market Size Market Share by Type (2025-2031)
Table 22. United States siRNA Drugs Market Size by Application (2025-2031) ($ millions)
Table 23. United States siRNA Drugs Market Size Market Share by Application (2025-2031)
Table 24. Europe siRNA Drugs Market Size by Type (2025-2031) ($ millions)
Table 25. Europe siRNA Drugs Market Size Market Share by Type (2025-2031)
Table 26. Europe siRNA Drugs Market Size by Application (2025-2031) ($ millions)
Table 27. Europe siRNA Drugs Market Size Market Share by Application (2025-2031)
Table 28. China siRNA Drugs Market Size by Type (2025-2031) ($ millions)
Table 29. China siRNA Drugs Market Size Market Share by Type (2025-2031)
Table 30. China siRNA Drugs Market Size by Application (2025-2031) ($ millions)
Table 31. China siRNA Drugs Market Size Market Share by Application (2025-2031)
Table 32. Rest of World siRNA Drugs Market Size by Type (2025-2031) ($ millions)
Table 33. Rest of World siRNA Drugs Market Size Market Share by Type (2025-2031)
Table 34. Rest of World siRNA Drugs Market Size by Application (2025-2031) ($ millions)
Table 35. Rest of World siRNA Drugs Market Size Market Share by Application (2025-2031)
Table 36. Key Market Drivers & Growth Opportunities of siRNA Drugs
Table 37. Key Market Challenges & Risks of siRNA Drugs
Table 38. Key Industry Trends of siRNA Drugs
Table 39. Company A Company Details
Table 40. Companies Invested by Company A
Table 41. Company A Key Development and Market Layout
Table 42. Company B Company Details
Table 43. Companies Invested by Company B
Table 44. Company B Key Development and Market Layout
Table 45. Company C Company Details
Table 46. Companies Invested by Company C
Table 47. Company C Key Development and Market Layout
Table 48. Alnylam Basic Information, Head Office, Major Market Areas and Its Competitors
Table 49. Alnylam siRNA Drugs Market Size (2024 VS 2030)
Table 50. Novartis Basic Information, Head Office, Major Market Areas and Its Competitors
Table 51. Novartis siRNA Drugs Market Size (2024 VS 2030)
Table 52. Novo Nordisk Basic Information, Head Office, Major Market Areas and Its Competitors
Table 53. Novo Nordisk siRNA Drugs Market Size (2024 VS 2030)
Table 54. Genzyme Basic Information, Head Office, Major Market Areas and Its Competitors
Table 55. Genzyme siRNA Drugs Market Size (2024 VS 2030)
Table 56. Arrowhead Basic Information, Head Office, Major Market Areas and Its Competitors
Table 57. Arrowhead siRNA Drugs Market Size (2024 VS 2030)
Table 58. Silence Basic Information, Head Office, Major Market Areas and Its Competitors
Table 59. Silence siRNA Drugs Market Size (2024 VS 2030)
Table 60. Sylentis Basic Information, Head Office, Major Market Areas and Its Competitors
Table 61. Sylentis siRNA Drugs Market Size (2024 VS 2030)
Table 62. Avidity Biosciences Basic Information, Head Office, Major Market Areas and Its Competitors
Table 63. Avidity Biosciences siRNA Drugs Market Size (2024 VS 2030)
Table 64. Sirnaomics Basic Information, Head Office, Major Market Areas and Its Competitors
Table 65. Sirnaomics siRNA Drugs Market Size (2024 VS 2030)
Table 1. siRNA Drugs Market Size CAGR by Region (2025-2031) ($ millions)
Table 2. Major Players of Intravenous Injection
Table 3. Major Players of Subcutaneous Injection
Table 4. Global Market Size by Type (2025-2031) ($ millions)
Table 5. Global siRNA Drugs Market Size Market Share by Type (2025-2031)
Table 6. Global siRNA Drugs Market Size by Application (2025-2031) ($ millions)
Table 7. Global siRNA Drugs Market Size Market Share by Application (2025-2031)
Table 8. Date of Global Key Players Enter into siRNA Drugs Market
Table 9. Global Key Players siRNA Drugs Product Offered
Table 10. Key Players siRNA Drugs Funding/Investment (Million USD)
Table 11. Funding/Investment by Regions
Table 12. Funding/Investment by End-Industry
Table 13. Key Players siRNA Drugs Valuation & Market Capitalization (Million USD)
Table 14. Key Players Mergers & Acquisitions, Expansion Plans
Table 15. siRNA Drugs New Product/Technology Launches
Table 16. siRNA Drugs Industry Partnerships, Agreements, and Collaborations
Table 17. siRNA Drugs Industry Mergers and Acquisitions
Table 18. Global siRNA Drugs Market Size by Regions 2025-2031 ($ millions)
Table 19. Global siRNA Drugs Market Size Market Share by Regions 2025-2031
Table 20. United States siRNA Drugs Market Size by Type (2025-2031) ($ millions)
Table 21. United States siRNA Drugs Market Size Market Share by Type (2025-2031)
Table 22. United States siRNA Drugs Market Size by Application (2025-2031) ($ millions)
Table 23. United States siRNA Drugs Market Size Market Share by Application (2025-2031)
Table 24. Europe siRNA Drugs Market Size by Type (2025-2031) ($ millions)
Table 25. Europe siRNA Drugs Market Size Market Share by Type (2025-2031)
Table 26. Europe siRNA Drugs Market Size by Application (2025-2031) ($ millions)
Table 27. Europe siRNA Drugs Market Size Market Share by Application (2025-2031)
Table 28. China siRNA Drugs Market Size by Type (2025-2031) ($ millions)
Table 29. China siRNA Drugs Market Size Market Share by Type (2025-2031)
Table 30. China siRNA Drugs Market Size by Application (2025-2031) ($ millions)
Table 31. China siRNA Drugs Market Size Market Share by Application (2025-2031)
Table 32. Rest of World siRNA Drugs Market Size by Type (2025-2031) ($ millions)
Table 33. Rest of World siRNA Drugs Market Size Market Share by Type (2025-2031)
Table 34. Rest of World siRNA Drugs Market Size by Application (2025-2031) ($ millions)
Table 35. Rest of World siRNA Drugs Market Size Market Share by Application (2025-2031)
Table 36. Key Market Drivers & Growth Opportunities of siRNA Drugs
Table 37. Key Market Challenges & Risks of siRNA Drugs
Table 38. Key Industry Trends of siRNA Drugs
Table 39. Company A Company Details
Table 40. Companies Invested by Company A
Table 41. Company A Key Development and Market Layout
Table 42. Company B Company Details
Table 43. Companies Invested by Company B
Table 44. Company B Key Development and Market Layout
Table 45. Company C Company Details
Table 46. Companies Invested by Company C
Table 47. Company C Key Development and Market Layout
Table 48. Alnylam Basic Information, Head Office, Major Market Areas and Its Competitors
Table 49. Alnylam siRNA Drugs Market Size (2024 VS 2030)
Table 50. Novartis Basic Information, Head Office, Major Market Areas and Its Competitors
Table 51. Novartis siRNA Drugs Market Size (2024 VS 2030)
Table 52. Novo Nordisk Basic Information, Head Office, Major Market Areas and Its Competitors
Table 53. Novo Nordisk siRNA Drugs Market Size (2024 VS 2030)
Table 54. Genzyme Basic Information, Head Office, Major Market Areas and Its Competitors
Table 55. Genzyme siRNA Drugs Market Size (2024 VS 2030)
Table 56. Arrowhead Basic Information, Head Office, Major Market Areas and Its Competitors
Table 57. Arrowhead siRNA Drugs Market Size (2024 VS 2030)
Table 58. Silence Basic Information, Head Office, Major Market Areas and Its Competitors
Table 59. Silence siRNA Drugs Market Size (2024 VS 2030)
Table 60. Sylentis Basic Information, Head Office, Major Market Areas and Its Competitors
Table 61. Sylentis siRNA Drugs Market Size (2024 VS 2030)
Table 62. Avidity Biosciences Basic Information, Head Office, Major Market Areas and Its Competitors
Table 63. Avidity Biosciences siRNA Drugs Market Size (2024 VS 2030)
Table 64. Sirnaomics Basic Information, Head Office, Major Market Areas and Its Competitors
Table 65. Sirnaomics siRNA Drugs Market Size (2024 VS 2030)
LIST OF FIGURES
Figure 1. Picture of siRNA Drugs
Figure 2. siRNA Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global siRNA Drugs Market Size Growth Rate 2025-2031 ($ millions)
Figure 7. siRNA Drugs Market Size by Region (2024 & 2031) ($ millions)
Figure 8. Global siRNA Drugs Market Size Market Share by Type (2025-2031)
Figure 9. Global Intravenous Injection Market Size Growth Rate
Figure 10. Global Subcutaneous Injection Market Size Growth Rate
Figure 11. siRNA Drugs in Nervous System Therapy
Figure 12. Global siRNA Drugs Market: Nervous System Therapy (2025-2031) ($ millions)
Figure 13. siRNA Drugs in Endocrine and Metabolic Therapy
Figure 14. Global siRNA Drugs Market: Endocrine and Metabolic Therapy (2025-2031) ($ millions)
Figure 15. siRNA Drugs in Others
Figure 16. Global siRNA Drugs Market: Others (2025-2031) ($ millions)
Figure 17. Global siRNA Drugs Market Size Market Share by Application (2025-2031)
Figure 18. Global siRNA Drugs Market Size in Nervous System Therapy Growth Rate
Figure 19. Global siRNA Drugs Market Size in Endocrine and Metabolic Therapy Growth Rate
Figure 20. Funding/Investment
Figure 21. Global siRNA Drugs Market Size Market Share by Regions 2025-2031
Figure 22. United States siRNA Drugs Market Size 2025-2031 ($ millions)
Figure 23. China siRNA Drugs Market Size 2025-2031 ($ millions)
Figure 24. Europe siRNA Drugs Market Size 2025-2031 ($ millions)
Figure 25. Rest of World siRNA Drugs Market Size 2025-2031 ($ millions)
Figure 26. United States siRNA Drugs Consumption Market Share by Type in 2029
Figure 27. United States siRNA Drugs Market Size Market Share by Application in 2029
Figure 28. Europe siRNA Drugs Consumption Market Share by Type in 2029
Figure 29. Europe siRNA Drugs Market Size Market Share by Application in 2029
Figure 30. China siRNA Drugs Consumption Market Share by Type in 2029
Figure 31. China siRNA Drugs Market Size Market Share by Application in 2029
Figure 32. Rest of World siRNA Drugs Consumption Market Share by Type in 2029
Figure 33. Rest of World siRNA Drugs Market Size Market Share by Application in 2029
Figure 1. Picture of siRNA Drugs
Figure 2. siRNA Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global siRNA Drugs Market Size Growth Rate 2025-2031 ($ millions)
Figure 7. siRNA Drugs Market Size by Region (2024 & 2031) ($ millions)
Figure 8. Global siRNA Drugs Market Size Market Share by Type (2025-2031)
Figure 9. Global Intravenous Injection Market Size Growth Rate
Figure 10. Global Subcutaneous Injection Market Size Growth Rate
Figure 11. siRNA Drugs in Nervous System Therapy
Figure 12. Global siRNA Drugs Market: Nervous System Therapy (2025-2031) ($ millions)
Figure 13. siRNA Drugs in Endocrine and Metabolic Therapy
Figure 14. Global siRNA Drugs Market: Endocrine and Metabolic Therapy (2025-2031) ($ millions)
Figure 15. siRNA Drugs in Others
Figure 16. Global siRNA Drugs Market: Others (2025-2031) ($ millions)
Figure 17. Global siRNA Drugs Market Size Market Share by Application (2025-2031)
Figure 18. Global siRNA Drugs Market Size in Nervous System Therapy Growth Rate
Figure 19. Global siRNA Drugs Market Size in Endocrine and Metabolic Therapy Growth Rate
Figure 20. Funding/Investment
Figure 21. Global siRNA Drugs Market Size Market Share by Regions 2025-2031
Figure 22. United States siRNA Drugs Market Size 2025-2031 ($ millions)
Figure 23. China siRNA Drugs Market Size 2025-2031 ($ millions)
Figure 24. Europe siRNA Drugs Market Size 2025-2031 ($ millions)
Figure 25. Rest of World siRNA Drugs Market Size 2025-2031 ($ millions)
Figure 26. United States siRNA Drugs Consumption Market Share by Type in 2029
Figure 27. United States siRNA Drugs Market Size Market Share by Application in 2029
Figure 28. Europe siRNA Drugs Consumption Market Share by Type in 2029
Figure 29. Europe siRNA Drugs Market Size Market Share by Application in 2029
Figure 30. China siRNA Drugs Consumption Market Share by Type in 2029
Figure 31. China siRNA Drugs Market Size Market Share by Application in 2029
Figure 32. Rest of World siRNA Drugs Consumption Market Share by Type in 2029
Figure 33. Rest of World siRNA Drugs Market Size Market Share by Application in 2029
More Publications
Global Vision Measuring Systems Market Growth (Status and Outlook) 2024-2030
US$ 3,660.00
February 2024
89 pages
Global DUV Lithography Machine Market Growth 2025-2031
US$ 3,660.00
November 2025
82 pages
Global Location Awareness Service Market Growth (Status and Outlook) 2024-2030
US$ 3,660.00
November 2024
82 pages
Global Cordless Phones With Answering Machine Market Growth 2025-2031
US$ 3,660.00
October 2026
109 pages
Global Discrete Semiconductor Modules Market Growth 2025-2031
US$ 3,660.00
November 2025
165 pages
